124 related articles for article (PubMed ID: 11911405)
1. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review.
Steensma DP; Harrison CN; Tefferi A
Leuk Lymphoma; 2001; 42(6):1243-53. PubMed ID: 11911405
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera.
Tefferi A; Elliott MA; Kao PC; Yoon S; El-Hemaidi I; Pearson TC
Blood; 2000 Aug; 96(4):1582-4. PubMed ID: 10942409
[TBL] [Abstract][Full Text] [Related]
3. Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature.
Burthem J; Chaudhry MS
Platelets; 2008 May; 19(3):234-5. PubMed ID: 18432524
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
Johansson P; Andréasson B
Clin Lab Haematol; 2006 Aug; 28(4):233-6. PubMed ID: 16898960
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
6. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A; Pereira A; Cervantes F; Arellano-Rodrigo E; Hernández-Boluda JC; Ferrer-Marín F; Angona A; Gómez M; Muiña B; Guillén H; Teruel A; Bellosillo B; Burgaleta C; Vicente V; Besses C
Blood; 2012 Feb; 119(6):1363-9. PubMed ID: 22160617
[TBL] [Abstract][Full Text] [Related]
7. Treatment of polycythemia vera with hydroxyurea.
Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
[TBL] [Abstract][Full Text] [Related]
8. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.
Weinfeld A; Swolin B; Westin J
Eur J Haematol; 1994 Mar; 52(3):134-9. PubMed ID: 8168592
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
11. A novel thrombopoietin signaling defect in polycythemia vera platelets.
Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
[TBL] [Abstract][Full Text] [Related]
12. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
Grunwald MR; Kuter DJ; Altomare I; Burke JM; Gerds AT; Walshauser MA; Savona MR; Stein B; Oh ST; Colucci P; Parasuraman S; Paranagama D; Mesa R
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):219-225. PubMed ID: 32063527
[TBL] [Abstract][Full Text] [Related]
14. Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea.
Castello G; Lerza R; Cerruti A; Cavallini D; Bogliolo G; Pannacciulli I
Ann Hematol; 1995 Sep; 71(3):119-21. PubMed ID: 7548329
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea and periodicity in myeloproliferative disease.
Bennett M; Grunwald AJ
Eur J Haematol; 2001 May; 66(5):317-23. PubMed ID: 11422411
[TBL] [Abstract][Full Text] [Related]
16. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
[TBL] [Abstract][Full Text] [Related]
17. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR; Hankins WD; Spivak JL
N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
[TBL] [Abstract][Full Text] [Related]
18. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
19. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
20. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
